This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Neogen (NEOG) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of 11.11% and 5.07%, respectively, for the quarter ended August 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Neogen (NEOG) Q1 Earnings Expected to Decline
by Zacks Equity Research
Neogen (NEOG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OMRI Clears NEOGEN's AquaPrime Peraside 15 as USDA Compliant
by Zacks Equity Research
NEOGEN (NEOG) completes organic certified water treatment program with the latest certification.
Should You Invest in the Invesco SP SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Why Is Neogen (NEOG) Up 0.7% Since Last Earnings Report?
by Zacks Equity Research
Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
EPA Validates NEOGEN's Disinfectant for Use Against COVID-19
by Zacks Equity Research
NEOGEN's (NEOG) BioSentry 904 Disinfectant approved by the EPA for use against the COVID-19-causing SARS-CoV-2 virus.
Should You Invest in the Invesco SP SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Neogen (NEOG) Q4 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
Neogen's (NEOG) Animal Safety revenues improve in the fourth quarter on strong sales of cleaners, disinfectants and sanitizers.
Neogen (NEOG) Q4 Earnings Top Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of 3.33% and -1.69%, respectively, for the quarter ended May 2020. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the Invesco SP SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Should You Invest in the Invesco SP SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Neogen (NEOG) Introduces Upgraded Igenity Beef Genomic Profile
by Zacks Equity Research
Neogen (NEOG) looks to provide better technology and information to commercial beef producers to take better decisions for their profitability.
Neogen (NEOG) Up 15.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Neogen (NEOG) Q3 Earnings & Revenues Miss, Margins Decline
by Zacks Equity Research
Neogen's (NEOG) fiscal third-quarter 2020 results reflect strength in the Animal Safety segment.
Neogen (NEOG) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of -14.81% and -2.22%, respectively, for the quarter ended February 2020. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Neogen (NEOG) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Neogen (NEOG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neogen Expands With Cell Biosciences' Food Safety Asset Buyout
by Zacks Equity Research
Neogen (NEOG) expands presence in Australia with asset buyout from Cell BioSciences.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Sweta Killa
Sector ETF report for PSCH
Neogen (NEOG) Up 6.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Neogen Expands in South America With Productos Acquisition
by Zacks Equity Research
Neogen (NEOG) expands operations in South America by acquiring its food safety diagnostics distributor partner that operates in Argentina and Uruguay.
Neogen (NEOG) Q2 Earnings & Revenues Miss, Margin Rises
by Zacks Equity Research
Neogen Corporation (NEOG) disappoints investors with dismal second-quarter fiscal 2020 results. However, the Food Safety segment showcased a robust performance.
Neogen (NEOG) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of -3.12% and -3.66%, respectively, for the quarter ended November 2019. Do the numbers hold clues to what lies ahead for the stock?
Neogen's (NEOG) Soleris for EBAC Receives AOAC's Clearance
by Zacks Equity Research
Neogen's (NEOG) Soleris test gets clearance from the AOAC, paving the way for efficient prevention of food contamination.
Neogen's Food Safety Business Thrives on Ergot Alkaloids Test
by Zacks Equity Research
The newly-developed Reveal Q+ MAX test is likely to fortify Neogen's (NEOG) presence in the global food allergen testing market.